Pricing Log in Create free account
Friday 6 November 2026 Export BIO’s income statement to Excel — free account

Bio-Rad Laboratories, Inc.

BIO Healthcare Medical Devices

Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024.

Revenue
+0.52%
EPS
+234.9%
Free cash flow
+8.07%
Total debt
+0.11%

Quarter to September 2026, against a year earlier

381.91 12.91 +3.50%
Market cap
$9.9B
P/E
9.7×
Fwd P/E
44.7×
Dividend yield
—
F-score
5/9
Altman Z
3.20
Beneish M
−2.29
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Bio-Rad Laboratories, Inc. (BIO) EV/EBITDA

Alert me on EV/EBITDA

Bio-Rad Laboratories, Inc. has no meaningful EV/EBITDA: its trailing twelve-month EBITDA is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 189× (August 2026) — the current reading is the lowest in ten years.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 168× 412.77%
FY2024 32.7× 20.62%
FY2023 27.1× 9.28%
FY2022 24.8× (42.68%)
FY2021 43.3× 11.50%
FY2020 38.9× (13.89%)
FY2019 45.1× —
FY2018 0.0× —
FY2017 30.3× 1.15%
FY2016 30.0× 35.49%

Quarterly newest first

Period EV/EBITDA Change
Sep 2026 0.0× —
Jun 2026 140× 12.79%
Mar 2026 124× (26.01%)
Dec 2025 168× 413.88%
43 more quarters

Against its own ten years

Low 0.0× High 189×
Ten-year median 29.6×
Current reading's percentile 9

EV/EBITDA against peers

Company EV/EBITDA
BIO Bio-Rad Laboratories, Inc. n/m
GKOS Glaukos Corporation compare n/m
TXG 10x Genomics compare n/m
BIO.B Bio-Rad Laboratories, Inc. compare n/m
SNN Smith & Nephew SNATS, Inc. compare 6.5×
GMED Globus Medical, Inc. compare 11.9×
PODD Insulet Corporation compare 16.1×
PEN Penumbra, Inc. compare 57.3×
BRKR Bruker Corporation compare 66.0×
Medical Devices industry median 11.5×
Healthcare sector median 8.4×
Market median 10.9×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on BIO